首页> 外文会议>Annual conference of the Veterinary Cancer Society >IDENTIFICATION OF THE TYROSINE KINASE RECEPTOR KIT AS A MOLECULAR TARGET IN NEOPLASTIC FELINE MAST CELLS
【24h】

IDENTIFICATION OF THE TYROSINE KINASE RECEPTOR KIT AS A MOLECULAR TARGET IN NEOPLASTIC FELINE MAST CELLS

机译:鉴定酪氨酸激酶受体试剂盒作为肿瘤猫型肥大细胞的分子靶标

获取原文

摘要

Systemic mastocytosis (SM) in felines is a rare neoplasm defined by increased growth and accumulation of immature mast cells (MC) in various organ systems. In advanced SM, the prognosis is grave. In these patients, neoplastic MC usually show a poor response to conventional drug therapy. Recent data suggest that Kit-targeting drugs may interfere with growth of neoplastic MC in humans. In this study, we examined the effects of four Kit tyrosine kinase inhibitors (TKI), imatinib (STI571), midostaurin (PKC412), nilotinib (AMN107), and dasatinib (BMS354825), on growth of feline neoplastic MC.
机译:Felines中的全身乳细胞增长症(SM)是一种罕见的肿瘤,通过增加各种器官系统中未成熟肥大细胞(MC)的增长和积累而定义。在高级SM中,预后是坟墓。在这些患者中,肿瘤MC通常表现出对常规药物治疗的不良反应。最近的数据表明,试剂盒靶向药物可能会干扰人类肿瘤MC的生长。在这项研究中,我们研究了四个试剂蛋白激酶抑制剂(TKI),伊马替尼(STI571),中豚(PKC412),尼洛替尼(AMN107)和Dasatinib(BMS354825)的效果对猫肿瘤MC的生长。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号